A Sharper View of Brain Aneurysms: Spryte's nOCT Nears FDA Review

BEDFORD, MA – July 22, 2026 – Spryte Medical, a company at the forefront of neurovascular imaging, today announced a critical milestone that could reshape the treatment of brain aneurysms. The company has completed patient enrollment for its INSYTE Trial, a pivotal study of its proprietary nOCT Imaging System. This achievement clears a major hurdle on the path toward submitting the first-of-its-kind technology for U.S. Food and Drug Administration (FDA) approval.

The system, which uses light to generate microscopic, real-time images from inside the brain's delicate blood vessels, promises to give surgeons an unprecedented level of detail during life-or-death procedures. With the trial's enrollment phase complete, Spryte Medical is now preparing the data that could bring this powerful new tool into neurointerventional suites across the country.

The High-Stakes World of Brain Aneurysms

Intracranial aneurysms, or weak bulges in the walls of the brain's arteries, are a silent threat. An estimated 6.7 million people in the United States live with an unruptured brain aneurysm, many without any symptoms. While most of these will never pose a problem, a rupture can cause a devastating type of stroke known as a subarachnoid hemorrhage, which is fatal in up to 50% of cases and leaves many survivors with permanent neurological damage.

For decades, neurosurgeons have relied on two primary methods to secure these aneurysms: open surgical clipping, which involves placing a metal clip at the aneurysm's base, and minimally invasive endovascular therapy. The latter, now the dominant approach, involves navigating a catheter from an artery in the groin or wrist up into the brain. From there, surgeons can deploy tiny platinum coils to fill the aneurysm or place a stent-like 'flow diverter' in the parent vessel to redirect blood flow away from it.

While these techniques have advanced significantly, they are performed with a crucial limitation: surgeons can't directly see the vessel wall they are treating. Current imaging standards like Digital Subtraction Angiography (DSA)—the long-held 'gold standard'—provide a high-resolution silhouette of the blood vessel's interior. However, they reveal little about the health of the vessel wall itself, the precise interaction between a device and the tissue, or the progress of long-term healing. This lack of granular detail introduces a degree of uncertainty into high-stakes procedures.

Illuminating the Unseen with nOCT

Spryte Medical aims to replace that uncertainty with data-driven confidence. The company’s nOCT™ Imaging System is an adaptation of Optical Coherence Tomography (OCT), a technology that has already revolutionized cardiology by providing physicians with cross-sectional, micron-level images of coronary arteries. By engineering a system specifically for the smaller, more tortuous vessels of the brain, Spryte is bringing this power to neurointervention.

The nOCT system provides real-time, high-resolution images that can visualize the vessel wall, assess device placement with unparalleled accuracy, and monitor the biological response to treatment. For surgeons, this is like switching from a roadmap to a live, satellite-view of the terrain.

Physicians leading the INSYTE Trial have already witnessed its potential. “I have observed firsthand the unique insights that intravascular neuro-OCT imaging can provide into vascular disease, vessel wall and device–tissue interface,” said Ricardo Hanel, MD, PhD, a neurosurgeon at Baptist Health Jacksonville and Co-Principal Investigator of the trial. “I am excited about the higher levels of precision and confidence this will provide us, helping us to deliver the best possible treatment for our patients.”

His colleague, Co-Principal Investigator Demetrius Lopes, MD, a neurosurgeon at Advocate Health, highlighted the technology's potential to transform long-term care. “For the first time we will have a detailed longitudinal view of aneurysm treatment, therapeutic device response and healing,” he stated. This capability could finally allow clinicians to understand why some treatments succeed and others fail over time, enabling more personalized follow-up care and antiplatelet therapy regimens.

From Trial to Market: Spryte's Strategic Milestone

Completing enrollment in a major clinical trial is a significant financial and operational achievement for any medical device company. The INSYTE Trial successfully enrolled 65 subjects across eight leading medical centers in three countries in just five months, signaling strong enthusiasm from the clinical community. For Spryte Medical, it validates years of engineering and collaborative effort.

“Completing enrollment in the INSYTE Trial is a major achievement for Spryte Medical and reflects years of collaboration among physicians, clinical partners, engineers, and regulatory stakeholders,” said David W. Kolstad, the company's Chief Executive Officer. “We are excited to take the next step toward an FDA submission and ultimately bring this technology to neurointerventional teams across the United States.”

That next step involves navigating the FDA's most stringent regulatory pathway: Premarket Approval (PMA). As a novel Class III device, the nOCT system must be proven safe and effective through extensive clinical data. The successful completion of the INSYTE trial's enrollment is the foundation of that submission. While the review process is lengthy and rigorous, clearing this clinical milestone positions Spryte Medical as a potential disruptor in the multi-billion-dollar neurovascular device market.

Rather than competing directly with the makers of coils and flow diverters—companies like Medtronic, Stryker, and Johnson & Johnson—Spryte’s technology is complementary. If approved, nOCT could become an essential enabling platform that enhances the safety and efficacy of existing and future therapeutic devices, creating a new and valuable niche where Spryte has a powerful first-mover advantage.

A Paradigm Shift in Neurovascular Care

Spryte Medical describes itself not just as an imaging company, but as an “artificial intelligence and data company.” This points to the ultimate vision for the nOCT platform. The massive amount of high-resolution data generated by the system is a perfect substrate for machine learning algorithms. In the future, AI could analyze these intricate images to automatically identify subtle wall pathologies, predict rupture risk more accurately, or quantify healing, turning raw visual information into actionable clinical intelligence.

The journey from an investigational device to a new standard of care is long, but the completion of the INSYTE trial is a definitive leap forward. By promising to illuminate the microscopic details of the brain's most fragile structures, Spryte Medical’s nOCT technology is poised to provide neurointerventionalists with a level of precision that was previously unimaginable. This shift from anatomical shadows to biological certainty has the potential to fundamentally improve how brain aneurysms are understood and managed, offering a brighter future for millions of patients.